Atlas Trials

Open-Label Efficacy and Safety Study of Pozelimab in Patients With CD55-Deficient Protein-Losing Enteropathy (CHAPLE Disease)

Clinical trial NCT04209634 · COMPLETED

Trial details

NCT number
NCT04209634
Sponsor
Regeneron Pharmaceuticals
Status
COMPLETED
Phase
Phase 2, Phase 3
Study type
INTERVENTIONAL
CD55-deficient Protein-losing EnteropathyCHAPLE
Start date
2020-01-27
Primary completion
2021-11-09
Enrollment
10

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.